Roche Won't Extend Offer for Illumina as Shareholders Re-elect Flatley, Others to Board | GenomeWeb

This article has been updated with comments from an internal Illumina e-mail.

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Roche will not extend its tender offer for Illumina, the Swiss pharmaceuticals and diagnostics firm said today, ending its hostile bid for the San Diego firm for now.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The Wall Street Journal reports that National Institutes of Health Director Francis Collins' response to contamination concerns at the agency might have delayed care.

The final revision of the Common Rule doesn't include the proposed change requiring consent for leftover biospecimens.

The first Reproducibility Project: Cancer Biology papers show mixed results.

In Nature this week: mobile phone-based targeted DNA sequencing, and more.